Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. Ward AB, et al. Among authors: buchsbaum dj. MedComm (2020). 2020 Sep;1(2):121-128. doi: 10.1002/mco2.10. Epub 2020 Jun 25. MedComm (2020). 2020. PMID: 33073260 Free PMC article.
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC. Turner TB, et al. Among authors: buchsbaum dj. Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395. Oncotarget. 2017. PMID: 28498806 Free PMC article.
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
McCaw TR, Li M, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A, Randall TD. McCaw TR, et al. Among authors: buchsbaum dj. Cancer Immunol Immunother. 2019 Feb;68(2):175-188. doi: 10.1007/s00262-018-2262-5. Epub 2018 Oct 17. Cancer Immunol Immunother. 2019. PMID: 30334128 Free PMC article.
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC. Smith HJ, et al. Among authors: buchsbaum dj. Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761. Epub 2018 Nov 13. Cancer. 2018. PMID: 30423192 Free PMC article.
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
Doo DW, Meza-Perez S, Londoño AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, Starenki D, Cooper SJ, Buchsbaum DJ, Norian LA, Randall TD, Arend RC. Doo DW, et al. Among authors: buchsbaum dj. Ther Adv Med Oncol. 2020 Apr 14;12:1758835920913798. doi: 10.1177/1758835920913798. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32313567 Free PMC article.
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB, Ward A, Keeton AB, Chen X, Maxuitenko Y, Prakash A, Li F, Foote JB, Buchsbaum DJ, Piazza GA. Coley AB, et al. Among authors: buchsbaum dj. Adv Cancer Res. 2022;153:131-168. doi: 10.1016/bs.acr.2021.07.009. Epub 2021 Aug 26. Adv Cancer Res. 2022. PMID: 35101229 Review.
251 results